Clinical Trials Logo

Large B-cell Lymphoma clinical trials

View clinical trials related to Large B-cell Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05108805 Active, not recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Start date: December 2, 2021
Phase: N/A
Study type: Interventional

We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified criteria

NCT ID: NCT04690192 Active, not recruiting - Clinical trials for Large B-cell Lymphoma

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Start date: January 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.

NCT ID: NCT04566978 Active, not recruiting - DLBCL Clinical Trials

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

Start date: September 11, 2020
Phase: Early Phase 1
Study type: Interventional

The main purposes of this study include: Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767 Finding the best dose amount of 89Zr-DFO-REGN3767 Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767

NCT ID: NCT03642626 Active, not recruiting - Clinical trials for Acute Lymphoblastic Leukemia

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Start date: December 18, 2018
Phase:
Study type: Observational

This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.